ADC Therapeutics (ADCT) EBIT Margin (2023 - 2026)
ADC Therapeutics' (ADCT) quarterly EBIT Margin came in at 126.02% in Q1 2026, up 44326.0% year-on-year from N/an in Q1 2025, and up 35.91% quarter-over-quarter from 196.63% in Q3 2025.
ADC Therapeutics (ADCT) EBIT Margin (2023 - 2026) Analysis & Trends
ADC Therapeutics has disclosed EBIT Margin across 4 years of filings, most recently posting 126.02% for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn | -126.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -126.02% |
| Sep 30, 2025 | -196.63% |
| Jun 30, 2025 | -234.34% |
| Mar 31, 2025 | -569.28% |
| Sep 30, 2024 | -197.40% |
| Jun 30, 2024 | -170.53% |
| Mar 31, 2024 | -186.19% |
| Sep 30, 2023 | -249.42% |
| Jun 30, 2023 | -205.62% |